EN DE
Watch GI Innovation Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GI Innovation Inc. (358570) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of GI Innovation Inc. stock KRW 4,406, price KRW 7,000, that is 37.1% below the price, quality 40 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Health Care KR

GI Thin data Nov 16, 2026

GI Innovation Inc.

358570 · KQ

Far too expensive (fair value 37% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Quality 40/100 
Mixed Growth (revenue 3y +18.6 %/yr in KRW) 
Mixed vs. peers (2/5) 
Fair value 4,406 KRW · Strongly overvalued 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 23/100
Thin data 
Estimate
Watch GI Innovation Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

24,000 KRW 6,220 KRW Fair Value 4,406 KRW Mar 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

44‑month range 6,220 KRW – 24,000 KRW · fair‑value band 3,305 KRW – 5,508 KRW · the 7,000 KRW price screens above the 4,406 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow GI Innovation in your weekly email

Every Wednesday you see whether GI Innovation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Stock analysis

GI Innovation Inc. (358570) currently trades at 7,000 KRW, while our estimate is 4,406 KRW, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 3,305 KRW (bear) to 5,508 KRW (bull), the price of 7,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Health Care sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

GI Innovation Inc. reported revenue of 5.8B KRW in FY2025 versus 5.6B KRW in FY2021, a compound +1.0%/yr. Reported net income was −35.1B KRW in FY2025.

Key figures

Market cap 447B KRW (≈ $334M) Small · Return on equity −6,173% · Return on assets (EBIT) −56.9% (5-year average) · Free cash flow −39.8B KRW · Net debt 7.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 67% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Health Care peers we cover trades at −7% fair-value upside, at −37%, 358570 screens richer than that median.

Fair Value

Bear 3,305 KRW Fair Value 4,406 KRW Bull 5,508 KRW
Price 7,000 KRW · Downside -37.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 85
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 45
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 7
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−573.0% (2021) → −693.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

358570 screens overvalued: fair value 37% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare GI Innovation Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −37.1% · Below median
Profitability
Return on assets −27.6% · Below median
Balance sheet
Debt / equity 0.07× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 358570
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 358570
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 358570
argenx SE ARGX $950.95 $908.40 −4% vs 358570
CSL Limited CSL A$199.55 A$186.49 −7% vs 358570
Moderna, Inc MRNA $215.27 $135.64 −37% vs 358570
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 358570
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 358570
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 358570
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 358570

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GI Innovation Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GI Innovation Inc. Fair Value". https://www.fairvalue-calculator.com/stock/358570

Frequently asked questions

Is GI Innovation Inc. (358570) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 4,406 KRW versus a price of 7,000 KRW, about 37% lower (overvalued).
What is the fair value of 358570?
Our estimate for GI Innovation Inc. is 4,406 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 7,000 KRW.
What is the quality score of 358570?
GI Innovation Inc. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GI Innovation Inc. (358570)?
Our calculated price target is the estimate of 4,406 KRW (as of Nov 16, 2026). Cautious scenario 3,305 KRW, optimistic scenario 5,508 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the GI Innovation Inc. stock forecast for 2026?
Our estimate puts fair value at 4,406 KRW, about 37% lower versus a price of 7,000 KRW (overvalued). Cautious scenario 3,305 KRW, optimistic scenario 5,508 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of GI Innovation Inc. (358570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GI Innovation Inc. it is 4,406 KRW per share (as of Nov 16, 2026), against a price of 7,000 KRW.
Is GI Innovation Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 358570 trades above its calculated fair value: price 7,000 KRW, fair value 4,406 KRW, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 358570?
No. The price is what the market pays today (7,000 KRW); the fair value is what the company's own numbers justify (4,406 KRW). For GI Innovation Inc. the two are 2,594 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is GI Innovation Inc. worth?
The market values GI Innovation Inc. at about 447B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 7,000 KRW; our models calculate a fair value of 4,406 KRW per share.
What do the bullish and bearish scenarios say about 358570?
Our models span a range for GI Innovation Inc.: cautious scenario 3,305 KRW, base 4,406 KRW, optimistic 5,508 KRW per share (as of Nov 16, 2026, price 7,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GI Innovation Inc. (358570)?
Balance-sheet figures for GI Innovation Inc. (as of Nov 16, 2026): debt of 0.07 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 358570 from its 52-week high?
GI Innovation Inc. trades at 7,000 KRW, about 67% below its 52-week high of 20,900 KRW and 13% above the low of 6,220 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 4,406 KRW is for.
Which stocks are comparable to GI Innovation Inc.?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GI Innovation Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price 7,000 KRW, calculated fair value 4,406 KRW (−37%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. GI Innovation Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GI Innovation Inc. (358570)?
The closing price on Nov 17, 2026 was 7,000 KRW. Our estimate is 4,406 KRW, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GI Innovation Inc. right now?
The price sits above even our optimistic bull case (5,508 KRW). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of GI Innovation Inc.

How large is the market capitalisation of GI Innovation Inc. (358570)?
The market capitalisation of GI Innovation Inc. is 447B KRW (≈ $334M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of GI Innovation Inc. (358570)?
The return on equity (ROE) of GI Innovation Inc. is −6,173% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GI Innovation Inc. (358570)?
On an EBIT basis the return on assets of GI Innovation Inc. is −56.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does GI Innovation Inc. (358570) generate?
The free cash flow of GI Innovation Inc. is −39.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GI Innovation Inc. (358570) carry?
The net debt of GI Innovation Inc. is 7.6B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GI Innovation Inc. in the live analysis

One click puts GI Innovation Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.